Navigation Links
BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Date:10/19/2007

PRINCETON, N.J., Oct. 19 /PRNewswire/ -- BioWa, Inc. (BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants GSK non-exclusive rights to research and develop antibodies based on POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, and license fees. Other details of the agreement are not disclosed.

"GSK has long time remained a strong leader in the pharmaceutical industry for both innovation and marketing," said Dr. Masamichi Koike, President and CEO of BioWa. "With the breadth and depth of GSK research, we are pleased to partner with a company that has large capabilities in all sectors of research. This collaboration will fulfill BioWa's mission to create benefit of POTELLIGENT(R) Technology to patients as quickly as possible."

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanism of antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology significantly enhances ADCC activity of an antibody in vitro, thereby increasing the potential for improved activity in vivo.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd., Japan's pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of POTELLIGENT(R) Technology, which creates high ADCC monoclonal antibodies. Currently, BioWa is developing ADCC enhanced monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have POTELLIGENT(R) antibody products in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities. For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT(R) is the trademark of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a ... and error process by finding the right antidepressant faster. CNSDose speeds recovery ... relationship through a personalized approach to treatment. , A peer-reviewed and ...
(Date:5/18/2017)... , ... May 18, 2017 , ... ... on April 28, 2017 at the Prince Of Wales Private Hospital. The procedure ... at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , ...
(Date:5/18/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... May 17, 2017 , ... ... senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical ... In addition to his position at Eurofins and Cardinal Health, he was former Chief ...
(Date:5/18/2017)... ... 17, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, is honored that Jay Crowley was selected ... Brussels, Belgium. , Crowley played a crucial role in the development of the ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
Breaking Biology News(10 mins):